# Immunotherapy for Third Line Metastatic Colorectal Cancer

> **NCT04444622** · PHASE2 · COMPLETED · sponsor: **Mirror Biologics, Inc.** · enrollment: 29 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **BIOLOGICAL:** AlloStim

## Key facts

- **NCT ID:** NCT04444622
- **Lead sponsor:** Mirror Biologics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-12
- **Primary completion:** 2025-03-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04444622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04444622, "Immunotherapy for Third Line Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04444622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*